News

September 26, 2019

FDA Grants Abexinostat Fast Track Status for Follicular Lymphoma

News

Xynomic Pharmaceutical‘s abexinostat has received Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for follicular lymphoma, the company announced in a press release. ... Read more

September 24, 2019

Fate Therapeutics Plans Trials Testing Off-the-shelf NK Cell Therapy for Lymphoma, Leukemia

News

Fate Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to initiate clinical studies evaluating FT596, its off-the-shelf cell-based immunotherapy designed to target multiple tumor proteins. The ... Read more

September 20, 2019September 20, 2019

‘Be Bold, Be Bald!’ Day for Cancer Organizations Set for Oct. 18

News

In solidarity with cancer patients, including those with lymphoma, thousands of people throughout the U.S. are expected to sport bald caps Oct. 18 as part of an annual effort called ... Read more

September 19, 2019

LRF Encourages All to ‘Light It Red’ for September, Blood Cancer Awareness Month

News

To raise funds and disease awareness, as well as to encourage patients, the Lymphoma Research Foundation (LRF) is presenting its annual Light it Red (LIR) for Lymphoma effort. The September-long initiative is ... Read more

September 17, 2019

2K’s WWE Video Game Will Help Raise Awareness of Blood Cancers

News

In a campaign featuring World Wrestling Entertainment (WWE) superstar and leukemia survivor Roman Reigns, video game publisher 2K is partnering with the Leukemia & Lymphoma Society to heighten awareness around ... Read more

September 13, 2019

Partnership Aims to Identify DLBCL Patients Likely to Benefit from ADCT-402

News

ADC Therapeutics announced it partnered with Freenome to identify biomarkers that can help to predict which diffuse large B-cell lymphoma (DLBCL) patients are most likely to respond to ADCT-402 (loncastuximab tesirine), ... Read more

September 12, 2019September 12, 2019

Opdivo-Adcetris Combo Shows Promise in Advanced PMBL Patients in Trial

News

Combining Opdivo (nivolumab) with Adcetris (brentuximab vedotin) could be a promising option for people with advanced primary mediastinal B-cell lymphoma (PMBL), an aggressive and hard-to-treat disease, results from the CheckMate-436 ... Read more

September 10, 2019

Biosimilar ABP 798 Shows Similar Safety and Efficacy to Rituxan in Phase 3 Trial for Non-Hodgkin’s Lymphoma

News

ABP 798, a biosimilar to Rituxan (rituximab), is showing comparable efficacy results to its original product in a Phase 3 trial for non-Hodgkin’s lymphoma patients, the treatment’s co-developers, Amgen and Allergan, have ... Read more

September 6, 2019

Gazyva-Revlimid Effective for Certain Patients with Relapsed or Refractory Follicular Lymphoma, Trial Suggests

News

A combination of Gazyva (obinutuzumab) and Revlimid (lenalidomide) is effective for some patients with follicular lymphoma who failed prior treatments, including those with early relapses, according to a Phase 2 ... Read more

September 5, 2019

Inherited BRCA2 Mutations Linked to Risk of Non-Hodgkin’s Lymphoma in Children

News

Inherited mutations in the DNA repair gene BRCA2 — a well-known risk factor for breast and ovarian cancers in adults — also show a significant association with non-Hodgkin’s lymphoma in children ... Read more